Table 3.
Summary of adverse events
| Adverse Events | All grades, n (%) | Grade ≥ 3, n (%) |
|---|---|---|
| Any adverse event | 26 (96.3) | 25 (92.6) |
| Hypertension | 21 (77.8) | 16 (59.3) |
| Fatigue | 15 (55.6) | 0 (0) |
| Weight loss | 14 (51.9) | 4 (14.8) |
| Diarrhea | 9 (33.3) | 3 (11.1) |
| Proteinuria | 9 (33.3) | 2 (7.4) |
| Anorexia | 8 (29.6) | 3 (11.1) |
| Oral mucositis | 7 (25.9) | 1 (3.7) |
| TSH elevation | 7 (25.9) | n/a |
| Nausea | 6 (22.2) | 1 (3.7) |
| Palmar-plantar erythrodysesthesia syndrome | 6 (22.2) | 2 (7.4) |
| Infections | 5 (18.5) | 1 (3.7) |
| Pulmonary | 1 (3.7) | 1 (3.7) |
| Dental | 1 (3.7) | 0 (0) |
| Urinary tract infection | 2 (7.4) | 0 (0) |
| Pharyngitis | 1 (3.7) | 0 (0) |
| Elevated liver enzymes | 4 (14.8) | 1 (3.7) |
| Anemia | 2 (7.4) | 1 (3.7) |
| Decreased platelet count | 2 (7.4) | 0 (0) |
| Hypokalemia | 2 (7.4) | 2 (7.4) |
| Arthralgia | 1 (3.7) | 1 (3.7) |
| Colitis | 1 (3.7) | 0 (0) |
| Left ventricular systolic dysfunction | 1 (3.7) | 1 (3.7) |
| Maculo-papular rash | 1 (3.7) | 0 (0) |
| Pancreatitis | 1 (3.7) | 1 (3.7) |
| Posterior reversible encephalopathy syndrome | 1 (3.7) | 1 (3.7) |
| Vestibular disorder | 1 (3.7) | 1 (3.7) |
Abbreviation: TSH, thyroid stimulating hormone.